Generic name
Erlotinib: adverse event reports filed with FDA
13,630 reports list it as a suspect or interacting product, 2004–2026. Class: Kinase inhibitor. Also reported as Erlotinib Tablet 150mg, Erlotinib Tablet, Erlotinib Tablet 100mg.
- 13,630
- reports as suspect product
- 0.1% of all reports · about 615 a year
- 99
- reports, 12 months to June 2026
- 254 in the 12 months before
- 97.9%
- marked serious by the reporter
- 70.8% across the class
- 49.6%
- record death among outcomes, as reported
- 6,759 reports · not verified by FDA
Between May 2004 and June 2026, 13,630 adverse event reports received by FDA list erlotinib, a generic name as a suspect or interacting product. Reports that mention it only as a concomitant medication (463) are left out of every figure here.
In the 12 months to June 2026, 99 reports listed it, down 61% from 254 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 615 reports a year and 0.1% of the 20,646,523 reports in the database, and 1.6% of the reports for the kinase inhibitor class. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are death (31.4%), rash (10.7%) and diarrhoea (10.2%). A report can list several reactions, so shares add to more than 100%; 1,290 different terms appear across these reports. Death is recorded in 31.4% of these reports, a larger share than in the median kinase inhibitor drug (7.6%).
97.9% of the reports are marked serious by the reporter (70.8% across the class); 49.6% record death among the outcomes and 31% record hospitalisation, as reported. 50.9% of the reports came from consumers, and the largest patient age group is 45 to 64 (22.5%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Erlotinib reports recording the termmedian drug in kinase inhibitor
- Deaththe patient died; cause not stated by this term31.4%4,286
- Rashskin rash10.7%1,465
- Diarrhoealoose or frequent stools10.2%1,396
- Malignant neoplasm progression9.4%1,281
- Off label useused for a purpose or in a way not on the label6.8%928
- Fatiguetiredness5.4%736
- Nauseafeeling sick5.3%724
- Vomitingbeing sick4.3%586
- Dyspnoeashortness of breath4.1%562
- Disease progressionthe disease advanced4%542
- Astheniaweakness or lack of energy3.8%515
- Decreased appetitereduced appetite3.8%513
- Anaemialow red blood cells3.6%487
- Pneumonialung infection3.3%453
- Drug resistance3.2%439
- Dehydrationdehydration3%404
- Malaisegeneral feeling of being unwell2.8%387
- Pyrexiafever2.6%361
- Drug ineffectivethe medicine did not work as expected2.6%349
- Painpain, site not specified2.5%346
- Pleural effusionfluid around the lung2.3%317
- Weight decreasedweight loss2.2%298
- Abdominal painstomach or belly pain2.1%291
- Incorrect dose administeredthe wrong dose was given2.1%287
- Coughcough2.1%281
- Neutropenialow neutrophils, a type of white blood cell2%266
- Pulmonary embolisma blood clot in the lung2%266
- Hypertensionhigh blood pressure1.9%261
- Respiratory failurethe lungs could not supply enough oxygen1.9%257
- Dermatitis acneiform1.8%243
Top 30 of 1,290 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 100 drugs in the kinase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 849,161 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 53.9% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Non-small cell lung cancer | 3,771 | 27.7% |
| Lung neoplasm malignant | 1,801 | 13.2% |
| Pancreatic carcinoma | 881 | 6.5% |
| Lung adenocarcinoma | 665 | 4.9% |
| Malignant respiratory tract neoplasm | 544 | 4% |
| Lung carcinoma cell type unspecified stage 0 | 287 | 2.1% |
The indication field is filled in by the reporter and is often blank; shares are of all 13,630 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Erlotinib reports |
|---|---|---|
| Bevacizumab | 1,330 | 9.8% |
| Carboplatin | 841 | 6.2% |
| Gemcitabine | 730 | 5.4% |
| Avastin | 646 | 4.7% |
| Pemetrexed | 449 | 3.3% |
| Paclitaxel | 447 | 3.3% |
| Cisplatin | 410 | 3% |
| Osimertinib | 248 | 1.8% |
| Aspirin | 242 | 1.8% |
| Docetaxel | 229 | 1.7% |
Other products listed in reports where Erlotinib is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Erlotinib | Kinase inhibitor | All reports |
|---|---|---|---|
| Reports as suspect product | 13,630 | 849,161 | 20,646,523 |
| Share of that pool | — | 1.6% | 0.1% |
| Reports, latest 12 months | 99 | — | 1,332,454 |
| Marked serious | 97.9% | 70.8% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 496 | 190 | 91 |
| Hospitalisation recorded, per 1,000 reports | 310 | 264 | 213 |
| Consumer-filed share | 50.9% | 42.3% | 45.8% |
| Top term, share of reports | Death 31.4% | median 7.6% | 4.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the kinase inhibitor class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Ibrance | brand | 81,912 | 2,380 | 47.1% |
| Imbruvica | brand | 67,039 | 2,283 | 74.4% |
| Cabometyx | brand | 41,818 | 4,904 | 40.4% |
| Sutent | brand | 33,215 | 175 | 74.5% |
| Afinitor | brand | 30,706 | 161 | 71.3% |
| Sprycel | brand | 27,255 | 557 | 49.7% |
| Tasigna | brand | 24,911 | 328 | 70.9% |
| Kisqali | brand | 24,603 | 3,413 | 79.2% |
| Ofev | brand | 23,907 | 2,434 | 66.9% |
| Gleevec | brand | 23,132 | 81 | 74.7% |
| Tagrisso | brand | 23,085 | 1,410 | 92.3% |
| Lenvima | brand | 22,350 | 2,643 | 87.3% |
| Votrient | brand | 22,084 | 119 | 60.9% |
| Mekinist | brand | 17,070 | 916 | 64% |
| Inlyta | brand | 15,696 | 388 | 60.9% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Erlotinib reports
How many adverse event reports has FDA received for Erlotinib?
13,630 reports list Erlotinib as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 99 of them arrived in the latest 12 months. Another 463 list it only as a concomitant medication.
What reactions are recorded in Erlotinib reports?
death (31.4%), rash (10.7%), diarrhoea (10.2%), malignant neoplasm progression (9.4%) and off label use (6.8%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Erlotinib was responsible.
How serious are the reports?
97.9% are marked serious by the reporter. Among the outcomes recorded, 49.6% of reports include death and 31% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (50.9%), physician (22.2%) and other health professional (21.6%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Erlotinib rising?
99 reports in the 12 months to June 2026, down 61% from 254 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Erlotinib was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Erlotinib?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Erlotinib as a suspect or interacting product; reports listing it only as a concomitant medication (463) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.